G6PD and hyperinsulinemic hypoglycemia, familial, 4: Current FDA recommendations suggest remdesivir as a treatment for COVID-19 patients; however, those with G6PD deficiency may exhibit more severe side effects than those with in-tact G6PD as a result of a decreased threshold for processing ROS in the liver.